PARC: The Psycopharmacology and Addiction Research Centre
Addiction is one of the world’s biggest unmet medical needs. Substance and behavioural addictions affect over 1.3 billion people worldwide and all current treatments have high failure rates. Our team at the University of Exeter Psycopharmacology PARC have developed a therapy that has shown early promise in treating alcohol addiction.
Professor Celia Morgan who led the research at the University of Exeter is seconded to Awakn Life Sciences who have licensed this new therapy and is helping drive their R&D strategy. Working in industry has given visibility to Professor Morgan’s work in different sectors and developed a clear translational pathway through which we are able to work together to secure funding for the Phase 3 clinical trials and ensure the timely commercialisation of this innovative therapy.
Working in industry and particularly the psychedelic space has given me a huge insight into the dynamic nature of the biotech industry and how demands and priorities differ from academia.
My skills and profile have brought research strength and credibility to the organisation. Through links with the University we have been able to execute research projects and gain research funding that may not have otherwise been available to the company.
Read more from Professor Celia Morgan
Professor Celia Morgan
Professor of Psychopharmacology
